Jennifer Goralski, MD, has been consulted for several news articles reporting the FDA’s expansion of age limits for Trikafta to treat younger children with cystic fibrosis. Dr. Goralski was a lead principal investigator in the clinical trial on which the FDA based its decision. The articles can be found at the links below:
MedPage Today: FDA Extends Trikafta Approval to Even Younger Cystic Fibrosis Patients
Cystic Fibrosis News Today: FDA expands its approval of Trikafta to children ages 2 to 5
Pulmonary Advisor: Trikafta Approved for Children With Cystic Fibrosis as Young as 2 Years
RareDiseaseAdvisor: FDA Approves Trikafta Label Expansion for Young Children With Cystic Fibrosis